On June 12th, Gelonghui reported that Wuxi Bio (2269.HK) rebounded quickly, up 6% to HKD 11.58, with a total market value of HKD 48.1 billion. The company spent HKD 19.9234 million yesterday to repurchase 1.81 million shares at a repurchase price of HKD 10.98-11.08 per share. Despite concerns about the impact of the bill on the Wuxi Pharma series, the company continues to increase the number of newly signed projects for January and February 2024. As of March 22, 2024, the company has added 25 new projects.
港股异动丨药明生物反弹6% 昨日耗资近2千万回购股份
Hong Kong stocks are volatile. Wuxi Bio rebounded by 6%, and yesterday spent nearly 20 million yuan on repurchasing shares.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.